Vaccine maker Pfizer said Friday that trials of its vaccine in children ages 2 to 5 show that it did not provide the expected immunity in kids this age, and it is adding a third dose to the regimen.

The study will examine vaccine safety, efficacy and immunity at lower doses. Pfizer is advancing Phase 2/3 clinical trials for young kids at lower doses than vaccines for adults, the pharmaceutical ...

(NEXSTAR) – At the urging of the Food and Drug Administration, Pfizer and Moderna will be expanding their COVID-19 vaccine trials in children ages 5 to 11 as a precautionary measure after rare side ...

Pfizer and BioNTech said Tuesday they've begun clinical trials for an omicron-based COVID-19 vaccine. According to a press release, the vaccine will be tested initially in adults aged 18 to 55. "While ...

The ongoing Phase 3 clinical trial of Pfizer/BioNTech's coronavirus vaccine confirms its protection lasts at least six months after the second dose, the companies said Thursday. The companies can now ...

SAN FRANCISCO -- One of the front-runners in the quest for a COVID-19 vaccine is reporting hopeful news. Pfizer says its vaccine is proving to be safe during phase three trials. RELATED: Oxford, ...